No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ZYXI Zynex
- 10.100
- -0.190-1.85%
Close Jul 19 16:00 ET
- 9.950
- -0.150-1.49%
Post 16:55 ET
320.93MMarket Cap43.91P/E (TTM)
10.410High10.045Low98.65KVolume10.250Open10.290Pre Close1.01MTurnover0.64%Turnover Ratio37.41P/E (Static)31.78MShares13.77052wk High9.69P/B155.71MFloat Cap6.88052wk Low--Dividend TTM15.42MShs Float29.430Historical High--Div YieldTTM3.55%Amplitude4.208Historical Low10.201Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Zynex Sets Second Quarter 2024 Earnings Call
ENGLEWOOD, Colo., July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 36%?
Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces
ENGLEWOOD, Colo., July 11, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain
All You Need to Know About Zynex (ZYXI) Rating Upgrade to Buy
RBC Capital Reiterates Outperform on Zynex, Maintains $15 Price Target
RBC Capital analyst Shagun Singh reiterates Zynex (NASDAQ:ZYXI) with a Outperform and maintains $15 price target.
Zynex to Participate in Fireside Chat With RBC Capital Markets on Thursday, June 13, 2024
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for...
Comments
$Zynex(ZYXI.US$ could be coming to 8.35/9.35 area before doing the next wave up to that supply ara 18.62/19.14. please do your dd and this is not financial advice
$Zynex(ZYXI.US$ no good news?
Zynex's high P/E ratio is justified by its forecasted growth, outpacing the wider market. Investors anticipate strong future growth, showing less concern for potential earnings deterioration.
Several insiders selling shares over past year could signal a warning for potential investors. High insider ownership, recent selling trends, and lack of insider buying may cause investor caution.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg